Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.123.033669 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Xiaozeng Wang und 18 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital of Northern Theater Command Shenyang China. Hauptthemen laut MEDLINE: Cholesterol, LDL, Dyslipidemias, Hypercholesterolemia, PCSK9 Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background A phase 3 trial was conducted to evaluate the efficacy and safety of ongericimab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9, as an add‐on treatment to optimized lipid‐lowering therapy in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia. Methods and Results A total of 806 patients who were receiving stable and optimized lipid‐lowering therapy but did not achieve their low‐density lipoprotein cholesterol (LDL‐C) targets were enrolled and randomly assigned in a 2:1:2:1 ratio to receive either ongericimab 150 mg or matching placebo every 2 weeks, or ongericimab 300 mg or matching placebo every 4 weeks for 52 weeks. Efficacy and safety were evaluated in 802 patients who received at least 1 dose of ongericimab or placebo. The primary end point was the percentage change in LDL‐C from baseline to week 24. Our findings demonstrated that the least‐squares mean difference of percentage change in LDL‐C from baseline to week 24 was −67.7% (95% CI, −72.5% to −63.0%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Hospital of Northern Theater Command Shenyang China.
- The Fourth Hospital of Harbin Medical University Harbin China.
- Daqing People's Hospital Daqing China.
- Guangdong General Hospital Guangzhou China.
- The Affiliated Hospital of Xuzhou Medical University Xuzhou China.
- Peking University Third Hospital Beijing China.
ORCID-Profile: Xiaozeng Wang, Jiyan Chen, Zhouqing Huang, Zhijun Huang, Yihong Sun, Yi Zhao, Xuelian Bai, Yaling Han
Zitieren
APA
Wang, X., Qiu, M., Cheng, Z., Ji, X., Chen, J., Zhu, H., Tang, Y., Huang, Z., Su, G., Wang, G., Huang, Z., Yao, Z., Lin, J., Sun, Y., Li, S., Shao, C., Zhao, Y., Bai, X., & Han, Y. (2024). Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.033669
Vancouver
Wang X, Qiu M, Cheng Z, Ji X, Chen J, Zhu H, et al. Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.033669
BibTeX
@article{Wang2024,
author = {Wang, Xiaozeng and Qiu, Miaohan and Cheng, Zhifeng and Ji, Xianyou and Chen, Jiyan and Zhu, Hong and Tang, Yida and Huang, Zhouqing and Su, Guohai and Wang, Gaopin and Huang, Zhijun and Yao, Zhuhua and Lin, Jinxiu and Sun, Yihong and Li, Shunhui and Shao, Cong and Zhao, Yi and Bai, Xuelian and Han, Yaling},
title = {Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.123.033669}
}
EUVIMED